PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32252811-0	2020	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.	Everolimus	0-10	CREB regulated transcription coactivator 1	Mus musculus	137-143	
32252811-2	2020	Based on results of the BOLERO-2 trial, the mTORC1 inhibitor everolimus in combination with the steroidal aromatase inhibitor (AI) exemestane has become a standard treatment for patients with HR+ HER2- mBC resistant to prior non-steroidal AI therapy.	Everolimus	61-71	CREB regulated transcription coactivator 1	Mus musculus	44-50	
32252811-4	2020	Therefore, two different molecules targeting the PI3K/AKT/mTORC1 axis, namely everolimus and alpelisib, are available for patients progressing on/after previous AI treatment, but it is unclear how to optimize their use in the clinical practice.	Everolimus	78-88	CREB regulated transcription coactivator 1	Mus musculus	58-64